Huinian Zhou

945 total citations
27 papers, 559 citations indexed

About

Huinian Zhou is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Huinian Zhou has authored 27 papers receiving a total of 559 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Oncology and 8 papers in Surgery. Recurrent topics in Huinian Zhou's work include Pancreatic and Hepatic Oncology Research (5 papers), Gastrointestinal Tumor Research and Treatment (5 papers) and Gastric Cancer Management and Outcomes (5 papers). Huinian Zhou is often cited by papers focused on Pancreatic and Hepatic Oncology Research (5 papers), Gastrointestinal Tumor Research and Treatment (5 papers) and Gastric Cancer Management and Outcomes (5 papers). Huinian Zhou collaborates with scholars based in China, United States and Australia. Huinian Zhou's co-authors include Zeyuan Yu, Zuoyi Jiao, Lei Zhang, Xia Long, Jiatong Lin, Baojia Zou, Jun Zheng, Liang Qiao, Jianye Cai and Jingwen Peng and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Huinian Zhou

25 papers receiving 550 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Huinian Zhou China 10 390 207 146 90 53 27 559
Zhuanpeng Chen China 10 258 0.7× 195 0.9× 136 0.9× 56 0.6× 57 1.1× 15 420
Side Liu China 16 510 1.3× 316 1.5× 158 1.1× 110 1.2× 81 1.5× 22 744
Lantian Tian China 11 301 0.8× 218 1.1× 128 0.9× 85 0.9× 43 0.8× 21 549
Jason T. Godfrey United States 4 224 0.6× 100 0.5× 153 1.0× 106 1.2× 40 0.8× 5 404
Jianling Zou China 14 200 0.5× 122 0.6× 243 1.7× 119 1.3× 64 1.2× 18 467
Jia-Huan Lu China 9 560 1.4× 505 2.4× 175 1.2× 130 1.4× 31 0.6× 9 790
Sai Ge China 12 405 1.0× 286 1.4× 215 1.5× 164 1.8× 34 0.6× 21 708
Pina Ziranu Italy 12 200 0.5× 143 0.7× 251 1.7× 116 1.3× 67 1.3× 39 482
Katsuharu Saito Japan 13 256 0.7× 112 0.5× 208 1.4× 83 0.9× 159 3.0× 26 476
Hongle Li China 16 421 1.1× 267 1.3× 220 1.5× 191 2.1× 74 1.4× 44 724

Countries citing papers authored by Huinian Zhou

Since Specialization
Citations

This map shows the geographic impact of Huinian Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huinian Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huinian Zhou more than expected).

Fields of papers citing papers by Huinian Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huinian Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huinian Zhou. The network helps show where Huinian Zhou may publish in the future.

Co-authorship network of co-authors of Huinian Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Huinian Zhou. A scholar is included among the top collaborators of Huinian Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huinian Zhou. Huinian Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Peng, et al.. (2025). METTL3 Inhibition Restores PD-L1 Expression and CD8+ T-cell Cytotoxic Function in Immunotherapy-Treated Gastric Cancer. Cancer Immunology Research. 13(7). 1037–1052. 2 indexed citations
2.
Ren, Wen, Hu Han, Wei‐Wen Cai, et al.. (2025). ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation. Cell Death and Disease. 16(1). 597–597.
3.
Shi, Wengui, Zhijian Ma, Xiangyan Jiang, et al.. (2024). Targeting SHCBP1 Inhibits Tumor Progression by Restoring Ciliogenesis in Ductal Carcinoma. Cancer Research. 84(24). 4156–4172. 1 indexed citations
4.
Jiao, Zuoyi, Huinian Zhou, Bo Long, et al.. (2024). Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction cancer (GC/GEJC): A prospective, multi-center, phase II study.. Journal of Clinical Oncology. 42(16_suppl). e16108–e16108. 2 indexed citations
5.
Shi, Wengui, Jing Yang, Xiangyan Jiang, et al.. (2023). PICH Activates Cyclin A1 Transcription to Drive S-Phase Progression and Chemoresistance in Gastric Cancer. Cancer Research. 83(22). 3767–3782. 11 indexed citations
6.
Jiang, Xiangyan, Yong Ma, Tao Wang, et al.. (2023). Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress. Gastroenterology. 164(7). 1232–1247. 46 indexed citations
7.
Qin, Long, Junchang Zhang, Huinian Zhou, et al.. (2022). Therapeutic strategies targeting uPAR potentiate anti–PD-1 efficacy in diffuse-type gastric cancer. Science Advances. 8(21). eabn3774–eabn3774. 24 indexed citations
8.
Jiao, Zuoyi, Lixia Xiao, & Huinian Zhou. (2022). Present and Future Prospects of the Anti-cancer Activities of Saikosaponins. Current Cancer Drug Targets. 23(1). 2–14. 8 indexed citations
9.
Shi, Wengui, S. Zenz, Zhijian Ma, et al.. (2021). Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. Nature Communications. 12(1). 2812–2812. 55 indexed citations
10.
Yu, Zeyuan, Xiangyan Jiang, Long Qin, et al.. (2021). Correction: A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene. 40(14). 2622–2623. 5 indexed citations
11.
Guo, Lingyun, Zhenjiang Wang, Yuanyuan Du, et al.. (2020). Random-forest algorithm based biomarkers in predicting prognosis in the patients with hepatocellular carcinoma. Cancer Cell International. 20(1). 251–251. 39 indexed citations
12.
Pan, Zihao, Jianye Cai, Jiatong Lin, et al.. (2020). A novel protein encoded by circFNDC3B inhibits tumor progression and EMT through regulating Snail in colon cancer. Molecular Cancer. 19(1). 71–71. 170 indexed citations
13.
Yu, Zeyuan, Xiangyan Jiang, Long Qin, et al.. (2020). A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene. 40(5). 1027–1042. 78 indexed citations
14.
Yu, Zeyuan, et al.. (2020). Pancreatic fistula after pancreatoduodenectomy due to compression of the superior mesenteric vessels: a case report. BMC Surgery. 20(1). 170–170. 1 indexed citations
16.
Long, Bo, Zeyuan Yu, Huinian Zhou, et al.. (2018). Clinical characteristics and prognostic significance of galectins for patients with gastric cancer: A meta-analysis. International Journal of Surgery. 56. 242–249. 21 indexed citations
17.
Zenz, S., Changjiang Luo, Bin Zhao, et al.. (2017). [Small intestinal cavernous hemangioma causing chronic hemorrhage: a case report].. PubMed. 37(7). 866–868. 3 indexed citations
18.
Zenz, S., Jie Mao, Bin Zhao, et al.. (2017). Duodenal Bulb Adenocarcinoma Benefitted from Neoadjuvant Chemotherapy: A Case Report. Chemotherapy. 62(5). 290–294. 3 indexed citations
19.
Zhao, Guodong, Minggen Hu, Rong Liu, et al.. (2014). Single-port Retroperitoneoscopic Pancreatectomy. Journal of Clinical Gastroenterology. 48(6). 559–562. 4 indexed citations
20.
Yu, Zeyuan, et al.. (2014). [Laparoscopic cystogastrostomy with posterior approach for pancreatic pseudocyst drainage].. PubMed. 39(10). 1035–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026